Get the StoQuant digest — free

Free StoQuant digest by email. No account needed. See today's research picks.

Subscribe free

ANL vs CTMX — Stock Comparison

Compare ANL and CTMX side-by-side on StoQuant: ANL Q-Score 59 vs CTMX 74; analyst signal 71 vs 82. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.

Side-by-side snapshot

• ANL — Adlai Nortye Ltd. · Health Care · market cap $562M · Q-Score verdict Buy (59.0, grade B) · analyst signal 71/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: analyst consensus 71/100, valuation 50/100 · weakest signals: technicals 25/100, AI Alpha (gem) 14/100. Full ANL research.
• CTMX — CytomX Therapeutics, Inc. · Health Care · market cap $506M · Q-Score verdict Strong Buy (74.0, grade A) · analyst signal 82/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: analyst consensus 82/100, competitive moat 37/100 · weakest signals: AI Alpha (gem) 26/100, technicals 2/100. Full CTMX research.

What you can compare

• Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
• Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
• Insider activity: Cluster scores and recent Form 4 buying.
• Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
• Strategic edges: Competitive moat and durable advantage analysis.
• Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
• Macro context: Market regime and sector rotation alignment.

Deep dive: ANL research · CTMX research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →